Publications Office of the EU
Open house drug discount contracts brinzolamide and brimonidine, ATC S01EC24 - EU tenders
DisplayCustomHeader
Procurement Detail Actions Portlet
OP Portal - Procurement - Details

This page contains content generated automatically to improve findability and accessibility

- indicates text translated automatically in your browsing language

Open house drug discount contracts brinzolamide and brimonidine, ATC S01EC24 Text automatically translated in your browsing language Automatically translated

  • Published
    16/06/2025
  • Today
    17/07/2025
  • Deadline
    03/06/2027
Status
Published
Type of contract
Supplies
Subject for Renewal
No
Buyer
AOK Bayern - Die Gesundheitskasse
Place of performance
NUTS code: Multiple place of performance
Location of buyer
NUTS code: DE212 München, Kreisfreie Stadt
Business sector (Main CPV)
33600000 Pharmaceutical products
Total estimated contract value (excluding VAT)
Not available
Total final contract value (excluding VAT)
Not available
Tender reference number
25-089
Description

It is not an open procedure, but an open-house model! The open procedure form is only used because there is no form for the open house model. Contracts concluded in the open-house model are not subject to public procurement law due to the absence of a selection decision. Submission to procurement regulations is not associated with the use of this form. AOK Bayern intends to conclude non-exclusive discount agreements with all interested pharmaceutical companies on the active substance brinzolamide and brimonidine, ATC S01EC24, in accordance with § 130a(8) SGB V. AOK Bayern offers all interested pharmaceutical companies that meet the eligibility requirements listed below the conclusion of identical and non-individually negotiable discount agreements. The earliest possible start date is 01.08.2025, all contracts end on 31.07.2027. A contract can be concluded at any time during this term, but at the latest on 03.06.2027. Contracts may be terminated with a notice period of one month to the end of the month. Upon the entry into force of a rebate agreement for medicinal products with the active substance subject to the contract concluded by a federal or state-specific, open procedure, the open-house agreements automatically expire for the corresponding term. A contract is concluded with all interested pharmaceutical companies who prove their suitability by means of a completed and signed self-declaration of reliability. The pharmaceutical entrepreneur must submit the completed and signed contract (the signatory's right of representation must be derived from the extract from the commercial register, otherwise a power of attorney must be submitted) together with the completed and signed annex "Determination of the medicinal products covered by the contract" as well as the completed and signed self-declaration of reliability. The documents can either be signed in writing by hand or electronically with a qualified electronic signature. Documents signed by hand in WRITING form must be sent in duplicate in their original form to the following address: AOK Bayern - The health insurance awarding body SGB V ZE25 open-house discount agreements Carl-Wery-Str. 28 81739 Munich ELECTRONIC documents with a qualified electronic signature must be submitted via the communication area in the awarding portal www.dtvp.de. If complete and correct documents are received by the 3rd of each month, the contract starts on the following next month's first, otherwise on the following month's first. In the case of hand-signed documents in WRITTENFORM, the complete, completed and signed documents must be sent in advance by fax (089/62730650151), as a scan to the e-mail address vergabestelle1@by.aok.de or via the communication area in the procurement portal www.dtvp.de within the deadline if the complete and correct original documents in paper form are received by the AOK Bayern, contracting authority, by the 10th of the month. Please refer to the completion instructions, which are available at www.dtvp.de in the procurement documents. Interested pharmaceutical companies can request the activation of the procurement documents in the project room for the open-house procedure on the portal www.dtvp.de. A link to the portal can be found in this announcement. Only pharmaceutical companies can be considered as potential contractual partners. The documents of the open-house procedure are only released to pharmaceutical companies as potential contractual partners and must be treated as strictly confidential. By requesting the activation by the companies, the confidential treatment of the documents is confirmed. Text automatically translated in your browsing language Automatically translated

Submission Method
Electronic via:
https://www.dtvp.de/Satellite/notice/CXP4Y6Y5J2T
Tenders may be submitted
Electronic submission: allowed
https://www.dtvp.de/Satellite/notice/CXP4Y6Y5J2T
Information about a public contract, a framework agreement or a dynamic purchasing system (DPS)
The procurement involves the establishment of a framework agreement
Conditions for opening tenders (date)
Not available
Award method
Not available
Estimated value
Not available
Final contracted value
Not available
Award of contract
Not available
Prior information
Contract
Award
Footnote - legal notice

This content published on this page is meant purely as an additional service and has no legal effect. The Union's institutions do not assume any liability for its contents. The official versions of the relevant tendering notices are those published in the Supplement of Official Journal of the European Union and available in TED. Those official texts are directly accessible through the links embedded in this page. For more information please see Public Procurement Explainability and Liability notice.